Clinical trial

Daratumumab in STK11 Mutated NSCLC

NCT05807048

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-06-01

PhasePHASE2

Study timeline

Study start (actual)2023-06-01Date precision: day

Registry last updated2026-03-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancer With STK11/LKB1 Mutationunresolved

Interventions

Daratumumab and Hyaluronidase-fihjDRUG

Pre-Intervention MedicationDRUG

Post-Intervention MedicationDRUG

Sponsors & collaborators

NYU Langone Healthlead sponsor

Mapped research locations

New YorkNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05807048 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.